Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

JCO Precis Oncol · 2025 · PMC12184982 · PMID 40526879

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

showed a trendP = .089so close (0.05 < p ≤ 0.1)

The biomarker × treatment interaction for ImPrint was significant in the training IO arm versus control ( P = .045) and showed a trend in five IO arms combined versus control ( P = .089).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.